Reviva Pharmaceuticals Holdings, Inc. (RVPH)
After hours:
| Previous Close | 4.5600 |
| Open | 4.5500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 4.0100 - 4.6000 |
| 52 Week Range | 3.0300 - 9.2500 |
| Volume | |
| Avg. Volume | 1,133,072 |
| Market Cap | 114.327M |
| Beta (5Y Monthly) | 0.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6800 |
| Earnings Date | Nov 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.83 |
GlobeNewswireReviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering with several healthcare-focused institutional investors, and an investment vehicle managed
- GlobeNewswire
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated wit
- GlobeNewswire
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia – - Consistent Phase 3 RECOVER and Phase 2 REFRESH findings reinforce meaningful improvements across domains, well-tolerated safety, and low discontinuation rates for brilaroxazine vs. placebo – - Topline data from 1-year open-label extension (OLE)
